Want to see ICUI full AI Analyst Report?
ICUI Stock Chart & Stats
$182.24
$3.95(2.51%)
At close: 4:00 PM EDT
$182.24
$3.95(2.51%)
Day’s Range― - ―
52-Week Range$113.37 - $192.85
Previous CloseN/A
Volume199.31K
Average Volume (3M)242.86K
Market Cap
$4.02B
Enterprise Value$4.66B
Total Cash (Recent Filing)$298.30M
Total Debt (Recent Filing)$1.27B
Price to Earnings (P/E)134.0
Beta0.77
Next Earnings
Nov 09, 2026EPS Estimate
2.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.20
Shares Outstanding25,007,038
10 Day Avg. Volume213,089
30 Day Avg. Volume242,858
Financial Highlights & Ratios
PEG Ratio-47.74
Price to Book (P/B)1.66
Price to Sales (P/S)1.58
P/FCF Ratio38.29
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue2.16
Enterprise Value/Gross Profit5.75
Enterprise Value/Ebitda18.82
Forecast
1Y Price Target
$195.50Price Target Upside7.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)8.74
Revenue Forecast (FY)$2.19B
Bulls Say, Bears Say
Bulls Say
Core Business GrowthOrganic growth and record performance in pumps and consumables indicate healthy demand across core product families. Balanced expansion can strengthen ICU Medical’s hospital relationships, support scale benefits, and provide a durable foundation for revenue over the next several quarters.
Cash Generation And DeleveragingStrong free cash flow gives ICU Medical internal funding for operations while enabling debt reduction. Continued deleveraging should lower financial risk, improve resilience against business volatility, and create greater flexibility for product investment and other capital allocation priorities.
Recurring Consumables ModelThe installed infusion base and recurring use of sets, catheters, connectors, and other disposables create repeat purchasing beyond one-time capital equipment sales. This mix can improve revenue visibility and make the business less dependent on hospital pump replacement cycles.
Bears Say
Thin And Volatile ProfitabilityThe earnings recovery has not yet demonstrated consistent profitability across business cycles. Thin margins leave less protection against cost inflation, weaker product mix, or execution setbacks, while the recent history of losses reduces confidence that current earnings power will persist.
Tariff Cost BurdenRecurring tariff expense directly pressures gross profit and operating earnings unless offset by pricing, productivity, or sourcing actions. A $30–$40 million annual burden is material enough to constrain margin expansion and make the company’s earnings outlook more sensitive to trade-policy changes.
Regulatory And Product Timing RiskUncertain regulatory timing can delay commercialization of the Medfusion 5000 and postpone the revenue contribution expected from the program. Shifting installations also makes near-term demand less predictable, complicating planning and weakening confidence in the timing of growth investments.
ICU Medical News
ICUI FAQ
What was Icu Medical’s price range in the past 12 months?
Icu Medical lowest stock price was $113.37 and its highest was $192.85 in the past 12 months.
What is Icu Medical’s market cap?
Icu Medical’s market cap is $4.02B.
When is Icu Medical’s upcoming earnings report date?
Icu Medical’s upcoming earnings report date is Nov 09, 2026 which is in 18 days.
How were Icu Medical’s earnings last quarter?
Icu Medical released its earnings results on Aug 06, 2026. The company reported $2.37 earnings per share for the quarter, beating the consensus estimate of $1.914 by $0.456.
Is Icu Medical overvalued?
According to Wall Street analysts Icu Medical’s price is currently Undervalued.
Does Icu Medical pay dividends?
Icu Medical does not currently pay dividends.
What is Icu Medical’s EPS estimate?
Icu Medical’s EPS estimate is 2.14.
How many shares outstanding does Icu Medical have?
Icu Medical has 25,007,038 shares outstanding.
What happened to Icu Medical’s price movement after its last earnings report?
Icu Medical reported an EPS of $2.37 in its last earnings report, beating expectations of $1.914. Following the earnings report the stock price went up 10.933%.
Which hedge fund is a major shareholder of Icu Medical?
Currently, no hedge funds are holding shares in ICUI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ICU Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$195.50 (7.28% Upside)
$195.50 (7.28% Upside)
Blogger Sentiment
Bullish
ICUI Sentiment 60%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 9.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.1M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.92%
12-Months-Change
Fundamentals
Return on Equity
1.41%
Trailing 12-Months
Asset Growth
-3.31%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Icu Medical
ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps. Hemodialysis Solutions: Like Tego connectors and ClearGuard HD antimicrobial caps. Hazardous Drug Handling: With closed system transfer devices (ChemoClave, ChemoLock) and the Diana compounding system for safe preparation. They also provide a comprehensive range of intravenous (IV) solutions, diluents, and irrigation fluids, available in diverse packaging options like flexible containers and pour bottles. These include common formulations such as sodium chloride, dextrose, balanced electrolytes, lactated ringer's, mannitol, and sterile water, alongside specialized irrigation solutions like acetic acid and glycine. In medication management, ICU Medical offers sophisticated infusion pumps, including the Plum 360 and LifeCare PCA brands. Its advanced ICU Medical MedNet software enhances medication safety by integrating smart pumps with hospital electronic health records (EHRs), asset tracking, and alarm notification platforms. Accompanying professional services are also provided. For critical care environments, their portfolio features: Hemodynamic Monitoring: Systems like Cogent 2-in-1 and CardioFlo. Cardiac Output & Oximetry: TDQ, OptiQ, and TriOx catheters. Blood Pressure Transducers: Such as Transpac. Blood Sampling Systems: Including the SafeSet closed blood sampling and conservation systems. The company distributes its products to a wide spectrum of healthcare providers, including acute care hospitals, wholesalers, ambulatory clinics, and various alternate site facilities such as outpatient clinics, home healthcare services, and long-term care centers. Established in 1984, ICU Medical maintains its headquarters in San Clemente, California.
ICUI Company Deck
ICUI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a positive operational and financial trajectory: record revenues in key businesses, margin expansion, raised full-year guidance, and strong free cash flow enabled a $50M debt paydown and progress toward a ~2x leverage target. Headwinds remain — notably tariffs, currency impacts, restructuring charges, and a weakened Vital Care reported performance due to JV deconsolidation — and there is some timing uncertainty around regulatory resubmissions and project phasing. On balance, the company emphasized momentum and achievable margin/cash goals despite macro and one-time pressures.View all ICUI earnings summariesICUI Stock 12 Month Forecast
Average Price Target
$195.50
▲(7.28% Upside)
Technical Analysis
AngioDynamics
―
Baxter International
―
Becton Dickinson
―
Merit Medical Systems
―
Teleflex
―
Ownership Overview
1.77% Insiders
39.29% Mutual Funds
1.66% Other Institutional Investors
26.34% Public Companies and
Individual Investors